Journals / Gülhane Tıp Dergisi / 2014 / Cilt: 56 - Sayı: 1

Psoriazis hastalarında kardiyovasküler komorbiditeler cardiovascular comorbidities ın patients with psoriasis

Pages
70–72
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The high-risk group of patients with psoriasis may be candidates for early cardiovascular risk factor modification.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Psoriasis is chronic inflammatory disease that affects approximately 1-3% of the population.
📊
Key Findings & Data:Because of psoriasis and atherosclerosis are both characterized by helper and helper type 17 activation and reduced regulatory cell function.
💡
Conclusion & Impact:The high-risk group of patients with psoriasis may be candidates for early cardiovascular risk factor modification.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Psoriasis is chronic inflammatory disease that affects approximately 1-3% of the population. Psoriasis is associated with conventional cardiovascular risk factors, including hypertension, diabetes mellitus, obesity, smoking and hyperlipidaemia. Furthermore, psoriasis, like other type helper T-cell-driven inflammatory disorders such as rheumatoid arthritis and systemic lupus erythromatosus, is an independent risk factor for atherothrombotic disease. Because of psoriasis and atherosclerosis are both characterized by helper and helper type 17 activation and reduced regulatory cell function. Therefore, psoriasis is associated with increased risk of adverse cardiovascular events. Young age, severe skin affection and/ or psoriatic arthritis carry the most risk. The high-risk group of patients with psoriasis may be candidates for early cardiovascular risk factor modification.

Özet

Psoriazis popülasyonun yaklaşık 1-3'ünü etkileyen kronik, inflamatuvar bir hastalıktır. Psoriazis, hipertansiyon, diabetes mellitus, obezite, sigara kullanımı ve hiperlipidemiyi içeren geleneksel kardiyovasküler risk faktörleri ile ilişkilidir. Ayrıca, psoriazis, sistemik lupus eritematozus ve romatoid artrit gibi diğer helper aracılı inflamatuvar hastalıklara benzer şekilde, aterotrombotik hastalık için bağımsız bir risk faktörüdür. Çünkü hem psorazis, hem de arteroskleroz helper ve helper 17 aktivasyonu ve regiilatuvar hücre inhibisyonu ile karakterize hastalıklardır. Bu nedenle psoriazis, artmış kardiyovasküler olay riski ile ilişkilidir. Bu risk genç yaş, şiddetli deri tutulumu ve/veya psoriatik artrit varlığında en yüksektir. Yüksek risk grubundaki psoriazis hastaları erken kardiyovasküler risk faktörü modifikasyonu açısından aday olabilir.

🔖

Cite This Article

DEMİRKOL, S., BALTA, Ş., BALTA, İ. (2014). Psoriazis hastalarında kardiyovasküler komorbiditeler cardiovascular comorbidities ın patients with psoriasis. Gülhane Tıp Dergisi, Cilt: 56 - Sayı: 1, 70–72. https://ajindex.com/articles/215429

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM.Prevalence of cardiovascular risk factors in patients with psoriasis. Am Acad Dermatol 2006;55(5):82935
  2. Atakan N, Doğan S. Psoriasis, systemic disease? Turk Dermatol 2012;6(3):119--22
  3. Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, et al. Prevalence of metabolic syndrome in patients with psoriasis: hospital--based case-control study. Br Dermatol 2007;157(1):68--73
  4. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296(14):1735--41
  5. Gisondi P, FerrazziA, Girolomoni G. Metabolic comorbidities and psoriasis.Acta Dermatovenerol Croat 2010;18(4):297-- 304
  6. Xiao J, Chen LH, Tu YT, Deng XH, Tao J. Prevalence of myocardial infarction in patients with psoriasis in central China. Eur Acad Dermatol Venereol 2009;23(11):1311-5
  7. Balci DD, Balci A, Karazincir S, Ucar E, lyigun U, Yalcin F, et al. Increased carotid artery intima--media thickness and impaired endothelial function in psoriasis. Eur Acad Dermatol Venereol 2009;23(1):1-6
  8. Naldi L, Mercuri SR. Epidemiology of comorbidities in psoriasis. Dermatol Ther 2010;23(2):114--8
  9. Gelfand JM, Mehta NN, Langan SM. Psoriasis and cardiovascular risk: strength in numbers, part II. Invest Dermatol 2011;131 (5):1007--10
  10. Çelik R, Derviş E, Balaban D, Can G. Coexistence of Metabolic Syndrome and Psoriasis Vulgaris. Turkderm 2010;44(4):204--8
  11. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006;298(7):321--8
  12. Emre S, Metin A, Demirseren DD, Kilic S, Isikoglu S, Erel 0. The relationship between oxidative stress, smoking and the clinical severity of psoriasis. Eur Acad Dermatol Venereol 2012 Sep 25. doi: 10.1111/j.1468--3083.2012.04700.x. [Epub ahead of print]
  13. Mc Allister--Sistilli CG, Caggiula AR, Knopf S, Rose CA, MillerAL, Donny EC. The effects of nicotine on the immune system. Psychoneuroendocrinology 1998;23(2):175--87
  14. Sopori M. Effects of cigarette smoke on the immune system. Nat Rev Immunol 2002;2(5):372--7
  15. Armstrong AW, Schupp C, Bebo B. Psoriasis comorbidities: results from the national psoriasis foundation surveys 2003 to 2011. Dermatology 2012;225(2):121--6
  16. McDonald CJ, Calabresi P. Psoriasis and occlusive vascular disease. Br Dermatol 1978;99(5):469--75
  17. Kaye JA,